Vertex Pharmaceuticals (VRTX)
538.60
-4.02 (-0.74%)
NASDAQ · Last Trade: Nov 14th, 7:40 AM EST
News & Press Releases
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?fool.com
The stock has climbed more than 40% in one year.
Via The Motley Fool · November 14, 2026
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.
Via The Motley Fool · November 13, 2026
S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Sessionchartmill.com
Via Chartmill · November 11, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 Earnings: In-Line Revenue, Modest EPS Miss, Raised Guidance and Higher Spendingchartmill.com
Via Chartmill · November 2, 2026
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Vertex Pharmaceuticals earns steady profits from its cystic fibrosis medicines while expanding into new diseases. BioNTech has a large cash cushion and a growing cancer pipeline, but its COVID vaccine sales are fading.
Via The Motley Fool · November 11, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitationfool.com
These are among the best the industry has to offer.
Via The Motley Fool · November 8, 2026
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?fool.com
Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.
Via The Motley Fool · November 7, 2026
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Yearsfool.com
The drugmaker hasn't disappointed long-term shareholders.
Via The Motley Fool · November 5, 2026
Vertex to Participate in Upcoming Investor Conferences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · November 4, 2026
Vertex: 3 Key Takeaways for Long-Term Investorsfool.com
Vertex is betting on nephrology and rare endocrinology to build a fifth and fourth commercial pillar beyond cystic fibrosis.
Via The Motley Fool · November 3, 2026
Vertex (VRTX) Q3 2026 Earnings Call Transcriptfool.com
Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly.
Via The Motley Fool · November 3, 2026
VRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlook
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 11.8% year on year t...
Via StockStory · November 3, 2026
Vertex Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURNAVX and PALSONIFY.
Chief Executive Officer and President Reshma Kewalramani sa
Via MarketBeat · November 2, 2026
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reactionfool.com
Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.
Via The Motley Fool · November 2, 2026
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 11.8% year on year...
Via StockStory · November 2, 2026
Vertex Reports Third Quarter 2026 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · November 2, 2026
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...
Via StockStory · October 31, 2026
3 large-cap stocks with solid fundamentals
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Via StockStory · October 30, 2026
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fallchartmill.com
Via Chartmill · October 29, 2026
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenuefool.com
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
Via The Motley Fool · October 27, 2026
I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Movefool.com
Here's how I'm staying calm as valuations hit record highs.
Via The Motley Fool · October 26, 2026
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter Morefool.com
The company's gene-editing-focused platform looks promising.
Via The Motley Fool · October 24, 2026
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.fool.com
Vertex is expanding beyond its cystic fibrosis franchise.
Via The Motley Fool · October 24, 2026
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase IIImarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.
Chief Executive Officer and President Reshm
Via MarketBeat · October 23, 2026